Detalhe da pesquisa
1.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310904
2.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Breast Cancer Res Treat
; 189(1): 177-185, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34169393
3.
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 19(2): 229-239, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361469
4.
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(18): 4717-4722, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32284318
5.
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Clin Cancer Res
; 23(24): 7448-7453, 2017 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28774898
6.
Gemcitabine-induced pulmonary toxicity.
Anticancer Res
; 32(9): 4147-9, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22993376